Serhii Vakal
Turku, 20520, Finland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Inorganic carbon levels regulate growth via SigC signaling cascade in cyanobacteria.
Journal: The New phytologist
Published: April 07, 2025
Identification of potential dipeptidyl peptidase IV inhibitors from the ConMedNP library by virtual screening, and molecular dynamics methods.
Journal: Heliyon
Published: May 07, 2024
A2AR antagonist treatment for multiple sclerosis: Current progress and future prospects.
Journal: International review of neurobiology
Published: September 23, 2023
Virtual screening of natural products against 5-enolpyruvylshikimate-3-phosphate synthase using the Anagreen herbicide-like natural compound library.
Journal: RSC advances
Published: April 26, 2022
Nafamostat is a Potent Human Diamine Oxidase Inhibitor Possibly Augmenting Hypersensitivity Reactions during Nafamostat Administration.
Journal: The Journal of pharmacology and experimental therapeutics
Published: April 01, 2022
Advances in UDP-N-Acetylglucosamine Enolpyruvyl Transferase (MurA) Covalent Inhibition.
Journal: Frontiers in molecular biosciences
Published: March 04, 2022
Ganciclovir attenuates the onset and progression of experimental autoimmune uveitis by inhibiting infiltration of Th17 and inflammatory cells into the retina.
Journal: Biochemical pharmacology
Published: November 17, 2021
Enzyme-instructed self-assembly of peptide-drug conjugates in tear fluids for ocular drug delivery.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: August 26, 2021
A Rapid Corneal Healing Microneedle for Efficient Ocular Drug Delivery.
Journal: Small (Weinheim an der Bergstrasse, Germany)
Published: August 05, 2021
Drug-peptide supramolecular hydrogel boosting transcorneal permeability and pharmacological activity via ligand-receptor interaction.
Journal: Bioactive materials
Published: July 27, 2021
Heparin-binding motif mutations of human diamine oxidase allow the development of a first-in-class histamine-degrading biopharmaceutical.
Journal: eLife
Published: March 18, 2021
Last Updated: 09/26/2026